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Dendritic cells induce the activation of CD8 and CD4 T cells by presenting antigenic 
peptides on MHC class I and class II molecules, respectively. In a recent Science paper, 
Dudziak et al. (2007) reveal that these tasks are handled by distinct populations of 
dendritic cells in vivo.Adaptive immune responses are 
initiated by the stimulation of naive 
T lymphocytes by dendritic cells in 
the secondary lymphoid organs, 
such as the spleen and lymph 
nodes. Dendritic cells are distrib-
uted throughout the body, particu-
larly at the skin and the mucosal 
surfaces where pathogens are most 
frequently encountered. Upon cap-
turing antigens, the dendritic cells 
in peripheral tissue migrate into the 
local lymph node through the affer-
ent lymphatic vessels and present 
antigens to naive lymphocytes. In 
addition to these migrating dendritic 
cells, certain subsets of dendritic 
cells reside strictly in the secondary 
lymphoid organs and are collectively 
known as blood-derived dendritic 
cells. These dendritic cells arrive 
as precursors from the blood and 
differentiate into various subsets 
in situ. The blood-derived dendritic 
cells consist of two major subsets, 
CD8αα+ DEC205+ CD11b− (CD8+) 
and CD8αα− DEC205− CD11b+ (CD8− ) 
dendritic cells. Which of these den-
dritic cell populations are respon-
sible for priming CD4 and CD8 T 
cell responses in vivo? Dudziak and 
colleagues (2007) provide intrigu-
ing new evidence indicating that 
priming of these T cell subsets is 
preferentially handled by two types 
of blood-derived dendritic cells in 
the spleen. The authors reveal that 
the CD8+ and CD8− dendritic cells 
in the spleen can be distinguished 
by expression of lectins DEC205 
on CD8+ dendritic cells and DCIR2 
(dendritic cell inhibitory receptor-
2)—recognized by antibody 33D1—on CD8− dendritic cells (Figure 1). 
By making chimeric molecules of 
anti-DEC205 antibody fused to a 
model antigen, the authors showed 
that antigen is taken up by the 
CD8+ dendritic cells in vivo, which 
subsequently resulted in preferen-
tial stimulation of antigen-specific 
CD8 T cells. In contrast, injection 
of 33D1 antibody-antigen chimeric 
protein resulted in targeting of anti-
gen to the CD8− dendritic cells and 
subsequent stimulation of cognate 
CD4 T cells. Although both types of 
chimeric antibody-antigen proteins 
resulted in stimulation of both T cell 
subsets at high doses, a ten-fold 
difference in the efficiency of pres-
entation was detected.
Such preferential association of 
these dendritic cell subsets in prim-
ing of CD4 and CD8 T cells is con-
sistent with previous studies that 
have examined the ability of ex vivo 
isolated dendritic cell subsets to 
stimulate T cell responses following 
in vivo injection of protein antigens 
(Itano et al., 2003), cells (den Haan 
et al., 2000), or viruses (Allan et al., 
2003; Zhao et al., 2003). Specifi-
cally, CD8+ blood-derived dendritic 
cells are well known for their abil-
ity to present exogenous antigens 
on MHC class I molecules (Heath 
et al., 2004), in a process known 
as crosspriming. It was unclear 
whether the ability of CD8+ den-
dritic cells in crosspriming was due 
to their ability to capture the anti-
gen or to process and present the 
antigen on MHC class I. By isolat-
ing splenic dendritic cells that have 
captured equal number of antigen-Cell 128, Fecoated beads following systemic 
administration of labeled beads into 
mice, crosspresentation was shown 
to be much more efficient in CD8+ 
dendritic cells compared to CD8− 
dendritic cells (Schnorrer et al., 
2006). These results suggested that 
crosspresentation requires special-
ized machinery that is expressed by 
CD8+ but largely absent from CD8− 
dendritic cells. This was precisely 
what Dudziak et al. (2007) found: 
they demonstrated a striking divide 
between the CD8+ versus CD8− 
dendritic cells in their expression 
of genes important in class I versus 
class II MHC antigen-processing 
and presentation pathways (Figure 
1). This differential expression pat-
tern provided clear-cut evidence 
for the mechanism by which these 
dendritic cell subsets selectively 
present antigenic peptides to CD4 
and CD8 T cells.
As with all intriguing studies, sev-
eral key questions arise. Given that 
the CD8+ subset presents peptides 
on MHC class I and to a much lesser 
extent on MHC class II, how do they 
receive signals from T helper cells 
that are essential for the ability of 
dendritic cells to induce primary 
and/or memory cytotoxic T lym-
phocyte responses? Perhaps the 
number of MHC class II+ peptide 
complexes that form on the sur-
face of CD8+ dendritic cells, though 
inadequate for activating naive CD4 
T cells, is sufficient to receive help 
from effector CD4 T cells, which 
would have been induced by the 
CD8− dendritic cells. Second, 
although their study revealed the bruary 9, 2007 ©2007 Elsevier Inc. 435
figure 1. Antigen Presentation by CD8+ and CD8− Dendritic Cells
(Left) CD8+ dendritic cells express high levels of molecules required for crosspresentation on MHC class I. These include the TAP1-TAP2 complex, 
which transports small peptides into the class I loading compartment; the endoplasmic reticulum-associated degradation (ERAD) export system, 
which allows translocation of intravesicular protein to the cytosol; ERAAP, aminopeptidase associated with antigen processing; and ERp57, Tapasin 
(Tpsn), calreticulin (CRT), calnexin (CNX), which are all required for assembly of MHC class I heavy chain + β2m + peptide complex. The class I 
loading may occur in the ER or ER-phagosome-like compartments.
(Right) CD8− dendritic cells preferentially express molecules required for MHC class II processing and presentation. These include cathepsin family 
members, capable of fragmenting endocytosed proteins to provide ligands for MHC class II; γ-IFN-inducible lysosomal thiol reductase (GILT), which 
reduces proteins within the MHC class II loading compartment allowing exposure of residues for class II binding and protease trimming; and HLA-
DM, which catalyzes the exchange between class II-associated invariant chain peptide (CLIP) and antigenic peptides onto MHC class II molecules. 
These figures are based on Cresswell et al. (2005).division of labor by dendritic cell 
subsets to present soluble protein 
antigen injected systemically, do 
such rules apply also to infectious 
agents? Most infections begin at 
mucosal surfaces, and rapid and 
efficient induction of antimicrobial 
adaptive immunity is crucial for the 
survival of the host. Given that the 
dendritic cells in the lymph nodes 
have not been reported to express 
DCIR2 (Witmer and Steinman, 
1984), it would be interesting to test 
whether the DCIR2− CD8− dendritic 
cells in the lymph nodes possess 
similar affinity toward presentation 
of antigen on class II MHC. In a sim-
ilar vein, CD8+ and CD8− dendritic 
cells express different subsets of 
Toll-like receptors and presumably 
other pattern recognition receptors. 
It would be important to investigate 
how this relates to their differential 
ability to activate CD4 and CD8 T 
cells, particularly in response to 436 Cell 128, February 9, 2007 ©2007 Einfection or vaccination. Finally, 
because dendritic cells that migrate 
from tissues transport peripheral 
antigen to the lymph nodes (Allan 
et al., 2006), the relative contribu-
tions of these dendritic cells and the 
blood-derived ones (CD8+ and CD8− 
subsets) in priming CD4 T cells fol-
lowing local infection will need to 
be determined. Surely, the study by 
Dudziak and colleagues (2007) pro-
vides an important catalyst for future 
investigations to address these and 
other pertinent questions.
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